Literature DB >> 10979915

Risk factors for recurrent urinary tract infection in young women.

D Scholes1, T M Hooton, P L Roberts, A E Stapleton, K Gupta, W E Stamm.   

Abstract

To define host factors associated with an increased risk of recurrent urinary tract infection (RUTI), a case-control study was conducted in 2 populations: university women and health maintenance organization enrollees. Case patients were 229 women 18-30 years old with RUTIs; control subjects were 253 randomly selected women with no RUTI history. In a multivariate model, independent risk factors for RUTI included recent 1-month intercourse frequency (odds ratio [OR], 5.8; 95% confidence interval [CI], 3.1-10.6 for 4-8 episodes), 12-month spermicide use (OR, 1.8; 95% CI, 1.1-2.9), and new sex partner during the past year (OR, 1.9; 95% CI, 1.2-3.2). Two newly identified risk factors were age at first urinary tract infection (UTI) </=15 years (OR, 3.9; 95% CI, 1.9-8.0) and UTI history in the mother (OR, 2.3; 95% CI, 1.5-3.7). Blood group and secretor phenotype were not associated with RUTI. In young women, risk factors for sporadic UTI are also risk factors for recurrence. Two predictors suggest that genetic/long-term environmental exposures also predispose to RUTI.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10979915     DOI: 10.1086/315827

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  111 in total

1.  Lipocalin 2 imparts selective pressure on bacterial growth in the bladder and is elevated in women with urinary tract infection.

Authors:  Magnus Steigedal; Anne Marstad; Markus Haug; Jan K Damås; Roland K Strong; Pacita L Roberts; Stephanie D Himpsl; Ann Stapleton; Thomas M Hooton; Harry L T Mobley; Thomas R Hawn; Trude H Flo
Journal:  J Immunol       Date:  2014-11-14       Impact factor: 5.422

2.  The Role of Gram-Negative Bacteria in Urinary Tract Infections: Current Concepts and Therapeutic Options.

Authors:  Payam Behzadi; Edit Urbán; Mária Matuz; Ria Benkő; Márió Gajdács
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection.

Authors:  Thomas J Hannan; Makrina Totsika; Kylie J Mansfield; Kate H Moore; Mark A Schembri; Scott J Hultgren
Journal:  FEMS Microbiol Rev       Date:  2012-05       Impact factor: 16.408

4.  Guidelines for the diagnosis and management of recurrent urinary tract infection in women.

Authors:  Shawn Dason; Jeyapandy T Dason; Anil Kapoor
Journal:  Can Urol Assoc J       Date:  2011-10       Impact factor: 1.862

5.  Role of Behavioural Risk Factors in Symptoms Related to UTI Among Nursing Students.

Authors:  Shaili Vyas; Parul Sharma; Kajal Srivastava; Vipul Nautiyal; Ved Prakash Shrotriya
Journal:  J Clin Diagn Res       Date:  2015-09-01

6.  Similarity and divergence of phylogenies, antimicrobial susceptibilities, and virulence factor profiles of Escherichia coli isolates causing recurrent urinary tract infections that persist or result from reinfection.

Authors:  Yanping Luo; Yanning Ma; Qiang Zhao; Leili Wang; Ling Guo; Liyan Ye; Youjiang Zhang; Jiyong Yang
Journal:  J Clin Microbiol       Date:  2012-10-03       Impact factor: 5.948

Review 7.  Urinary tract infections in adult general practice patients.

Authors:  Eva Hummers-Pradier; Michael M Kochen
Journal:  Br J Gen Pract       Date:  2002-09       Impact factor: 5.386

8.  Persistence of uropathogenic Escherichia Coli in the bladders of female patients with sterile urine after antibiotic therapies.

Authors:  Shu-Cheng Liu; Xiao-Min Han; Ming Shi; Zi-Li Pang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-10-18

Review 9.  The role of probiotics in women with recurrent urinary tract infections.

Authors:  Turgay Akgül; Tolga Karakan
Journal:  Turk J Urol       Date:  2018-09-01

10.  Effect of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections: A Randomized Clinical Trial.

Authors:  Thomas M Hooton; Mariacristina Vecchio; Alison Iroz; Ivan Tack; Quentin Dornic; Isabelle Seksek; Yair Lotan
Journal:  JAMA Intern Med       Date:  2018-11-01       Impact factor: 21.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.